Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics

Molecular Therapy

Volumn 15, Issue 3, 2007, Pages 515-523

  Li, Shufeng ^a,b   Dong, Wei ^a,c   Zong, Yiwei ^a   Yin, Wu ^a   Jin, Guanghui ^a   Hu, Qingang ^a   Huang, Xiaofeng ^a   Jiang, Wenhui ^a   Hua, Zi Chun ^a  

^a NANJING UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE RELATED NON KINASE; PLASMID DNA; PLASMID VECTOR; POLYETHYLENEIMINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; GENE TARGETING; GENETIC CODE; GENETIC TRANSFECTION; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PROTEIN TARGETING; SURVIVAL TIME;

MUS;

EID: 33847211797     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300072     Document Type: Article

References (36)

1. Mays, SR and Nelson, BR (1999). Current therapy of cutaneous melanoma. Cutis 63: 293-298.
2. Rusthoven, JJ, Quirt, IC, Iscoe, NA, McCulloch, PB, James, KW and Lohmann, RC et al. (1996). Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14: 2083-2090.
3. Oktay, MH, Oktay, K, Hamele-Bena, D, Buyuk, A and Koss, LG (2003). Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum Pathol 34: 240-245.
4. Kornberg, LJ (1998). Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck-J Sci Spec 20: 745-752.
5. Owens, LV, Xu, L, Dent, GA, Yang, X, Sturge, GC and Craven, RJ et al. (1996). Focal adhesion kinase as a marker of Invasive potential in differentiated human thyroid cancer. Ann Surg Oncol 3: 100-105.
6. Schneider, GB, Kurago, Z, Zaharias, R, Gruman, LM, Schaller, MD and Hendrix, MJ (2002). Elevated focal adhesion kinase expression facilitates oral tumor cell invasion. Cancer 95: 2508-2515.
7. Sood, AK, Coffin, JE, Schneider, GB, Fletcher, MS, DeYoung, BR and Gruman, LM et al. (2004). Biological significance of focal-adhesion kinase in ovarian cancer: Role in migration and invasion. Am J Pathol 165: 1087-1095.
8. Tremblay, L, Hauck, W, Aprikian, AG, Begin, LR, Chapdelaine, A and Chevalier, S (1996). Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 68: 164-171.
9. Akasaka, T, Van Leeuwen, RL, Yoshinaga, IG, Mihm Jr., MC and Byers, HR (1995). Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines. J Invest Dermatol 105: 104-108.
10. 3 mediates K1735 murine melanoma cell motility in vivo and in vitro. J Cell Sci 114: 2665-2672.
11. Hess, AR, Postovit, LM, Margaryan, NV, Seftor, EA, Schneider, GB and Seftor, REB et al. (2005). Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 65: 9851-9860.
12. Ayaki, M, Komatsu, K, Mukai, M, Murata, K, Kameyama, M and Ishiguro, S et al. (2001). Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colourectal adenocarcinomas. Clin Cancer Res 7: 3106-3112.
13. Hauck CR, Hsia, DA, Puente, XS, Cheresh, DA and Schlaepfer, DD (2002). FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J 21: 6289-6302.
14. Filion, MC and Phillips, NC (1998). Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharm 162: 159-170.
15. Kornberg, L and Fleigel, J (2003). The effects of inducible overexpression of FAK-related non-kinase (FRNK) on a transformed epithelial cell line. Anticancer Res 23: 91-98.
16. Aguirre Ghiso, JA (2002). Inhibition of FAK signalling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21: 2513-2524.
17. Abdel-Ghany, M, Cheng, HC, Elble, RC and Pauli, BU (2002). Focal adhesion kinase activated by β4 integrin ligation to mCLCA1 mediates early metastatic growth. J Biol Chem 277: 34391-34400.
18. Moghimi, SM, Symonds, P, Murray, JC, Hunter, AC, Debska, G and Szewczyk, A (2005). A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 11: 990-995.
19. Urban-Klein, B, Werth, S, Abuharbeid, S, Czubayko, F and Aigner, A (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12: 461-466.
20. Ogris, M and Wagner, E (2002). Targeting tumors with non-viral gene delivery systems. Drug Discov Today 7: 479-485.
21. Curran, S and Murray, GI (2000). Matrix metalloproteinases: Molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 36: 1621-1630.
22. Nimesh, S, Goyal, A, Pawar, V, Jayaraman, S, Kumar, P and Chandra, R et al. (2006). Polyethylenimine nanoparticles as efficient transfecting agents for mammalian cells. J Control Release 110: 457-468.
23. Chollet, P, Favrot, MC, Hurbin, A and Coll, JL (2002). Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 4: 84-91.
24. Eliyahu, H, Servel, N, Domb, AJ and Barenholz, Y (2002). Upoplex-induced hemagglutination: Potential involvement in intravenous gene delivery. Gene Ther 9: 850-858.
25. Forrest, ML, Koerber, JT and Pack, DW (2003). A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery. Bioconjugate Chem 14: 934-940.
26. Godbey, WT, Wu, KK and Mikos, AG (1999). Poly(ethylenimine) and its role in gene delivery. J Control Release 60: 149-160.
27. Fischer, D, Bieber, T, Li, Y, Elsässer, H-P and Kissel, T (1999). A novel nonviral vector for DNA delivery based on low molecular weight, branched polyethylenimine: Effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 16: 1273-1279.
28. Coll, JL, Chollet, P, Brambilla, E, Desplanques, D, Behr, JP and Favrot, M (1999). In vivo delivery to tumors of DNA complexed with linear polyethylenimine. Hum Gene Ther 10: 1659-1666.
29. Hood, JD and Cheresh, DA (2002). Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100.
30. Hauck, CR, Sieg, DJ, Hsia, DA, Loftus, JC, Gaarde, WA and Monia, BP et al. (2001). Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res 61: 7079-7090.
31. Dong, W, Jin, GH, Li, SF, Sun, QM, Ma, DY and Hua, ZC (2006). Cross-linked polyethylenimine as potential DNA vector for gene delivery with high efficiency and low cytotoxicity. Acta Biochimica et Biophysica Sinica 38: 780-787.
32. Duarte, JDG, Nakamura, M and Ferreira, SH (1988). Participation of the sympathetic system in acetic-induced writhing in mice. Braz J Med Biol Res 21: 341-343.
33. Guthrie, HD, Welch, GR, Cooper, BS, Zakaria, AD and Johnson, LA (1994). Flow cytometric determination of degraded deoxyribonucleic acid in granulosa cells to identify atretic follicles during preovulatory maturation in the pig. Biol Reprod 50: 1303-1311.
34. Senger, DR (2002). The alpha(1) beta(1) and alpha(2) beta(1) integrins provide critical support for vascular endothelial growth factor signaling,endothelial cell migration, and tumor angiogenesis. Am J Pathol 160: 195-204.
35. 2 activation required for chemotaxis migration of vascular smooth muscle cells. J Biol Chem 275: 41092-41099.
36. Jia, LJ, Xu, HM, Ma, DY, Hu, QG, Huang, XF and Jiang, WH et al. (2005). Enhanced therapeutic effect by combination of tumor-targeting salmonella and endostatin in murin melanoma model. Cancer Biol Ther 4: 840-845.